The LRRK2 p.L1795F variant causes Parkinson’s disease in the Europeanpopulation
Lara M. Lange(National Institute on Aging), Zih‐Hua Fang(Benue State University), Kristin Levine(National Institutes of Health), Lenora Higginbotham(Emory University), Christine Klein(University of Lübeck), Hampton L. Leonard(National Institutes of Health), Alberto J. Espay(University of Cincinnati), Niccolò E. Mencacci(Universität Hamburg), Susan H. Fox(University of Toronto), Luca Marsili(University of Cincinnati), Stewart A. Factor(Georgetown University), Cornelis Blauwendraat(National Institutes of Health), Huw R. Morris(University College London), Dan Vitale(National Institutes of Health), Peter Bauer(Centogene (Germany)), Christian Beetz(Jena University Hospital), Hirotaka Iwaki(National Institute of Neurological Disorders and Stroke), Jessica Martin(National Institutes of Health), Nicole Kuznetsov(National Institutes of Health), Connie Marras(University of Toronto), Katja Lohmann(University of Lübeck), Mike A. Nalls(Alzheimer's Association), Honglei Chen(Central South University)
Cited by 1
Related Papers
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet Neurology|2017|2.3k
Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015
|The Lancet|2017|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k